Clinical Trial to Assess the Efficacy and Safety of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol for the Treatment of Seasonal Allergic Rhinitis

NCT00790023 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

707

Enrollment

INDUSTRY

Sponsor class

Conditions

Seasonal Allergic Rhinitis

Interventions

DRUG: 80 mcg Ciclesonide
DRUG: 160 mcg Ciclesonide
DRUG: Placebo

Sponsor

Sumitomo Pharma America, Inc.